
pmid: 25004225
handle: 2142/111001
Myriad took no prisoners on its way to the top of the molecular diagnostics field. That strategy is unlikely to endure.Myriad Genetics began in 1991 as a small University of Utah startup interested in the then-novel arena of diagnostic genetic testing. After winning a highly publicized race to sequence the BRCA1 and BRCA2 breast cancer genes, the company obtained patents on the gene sequences and methods of using them to determine cancer risk. The patents were broad and interlocking, covering BRCA genomic DNA, cDNA, methods of diagnosis and systems detecting mutations. Myriad also filed for diagnostic 'toolbox' patents, including two claiming any DNA primer or probe sharing 15 nucleotides with the wild-type BRCA1 or BRCA2 it first sequenced. These patents became the heart of the company.
Economic Competition, Ownership, Intellectual Property Law, intellectual property, United States, Patents as Topic, Supreme Court of the United States, patent, myriad, genetics, Genetic Testing, gene, supreme court, biotechnology, Biotechnology
Economic Competition, Ownership, Intellectual Property Law, intellectual property, United States, Patents as Topic, Supreme Court of the United States, patent, myriad, genetics, Genetic Testing, gene, supreme court, biotechnology, Biotechnology
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
